The FDA regulations governing disclosure of individual COIs require:
a Researchers to annually self-disclose financial COIs to the FDA
b Applicants submitting marketing applications to disclose financial COIs of researchers who conducted clinical studies
c Organizations to disclose financial COIs to the FDA no later than the time of submission of the IND application
d Sponsors to annually disclose to the FDA financial COIs of researchers who conducted clinical studies
A researcher calls you stating that he plans to submit a proposal to the NIH for a human subjects research study. He wants to know at what point he and his study team must submit COI disclosures to comply with the PHS regulation.
a Researchers must only submit COI disclosures if they have a significant financial interest related to the research
b No later than the time of proposal submission
c Never — the PHS regulation does not require researchers to submit COI disclosures
d Not until a notice of award is received
An example of an institutional COI is:
aThe organization’s president is a member of the board of trustees for a local non-profit organization that does not sponsor research at the organization
b An industry sponsor pays for the construction of a new research laboratory at the organization
c The organization gives scholarships to some post-doctoral researchers
d One of the organization’s deans is the vice-chair of the organization’s IRB
The COI management plan aims to:
a Eliminate all COIs in research when a COI is disclosed
b Reduce IRB review burden when a COI is disclosed
c Address disclosure of COIs in multi-center research when a COI is disclosed
d Provide procedures or extras steps to be taken to minimize the risk of bias when a COI is disclosed
The Correct Answer and Explanation is :
Correct Answers:
- FDA Regulations Governing Disclosure of Individual COIs:
b. Applicants submitting marketing applications to disclose financial COIs of researchers who conducted clinical studies - Point of COI Disclosures for NIH Proposals:
b. No later than the time of proposal submission - Example of Institutional COI:
b. An industry sponsor pays for the construction of a new research laboratory at the organization - Purpose of a COI Management Plan:
d. Provide procedures or extra steps to be taken to minimize the risk of bias when a COI is disclosed
Explanation:
1. FDA Regulations Governing COIs
The FDA requires applicants submitting marketing applications (e.g., New Drug Applications or NDAs) to disclose financial COIs of researchers who conducted clinical studies. This ensures transparency and mitigates risks of bias in study outcomes. Researchers themselves do not report directly to the FDA; sponsors manage these disclosures as part of their compliance responsibility.
2. NIH Proposal COI Disclosure Timing
For compliance with Public Health Service (PHS) regulations, researchers must disclose financial COIs no later than the time of proposal submission. This proactive approach ensures the NIH is aware of potential conflicts before funding decisions, promoting unbiased decision-making and integrity in research.
3. Institutional COI Example
An institutional COI arises when an organization’s financial interests might compromise research integrity. An example is when an industry sponsor funds a research lab, potentially creating financial dependence. This differs from unrelated community involvement or internal scholarships, which do not directly influence research integrity.
4. COI Management Plan Purpose
A COI management plan provides procedures to address potential biases and maintain research credibility. Its goal is not to eliminate all COIs (impractical in some cases) but to implement safeguards such as independent oversight, data monitoring, or disclosing conflicts in publications. This promotes transparency and mitigates bias, protecting research integrity.